Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Lingyan Weng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Special Environmental Medicine, Medical School, Nantong University, Nantong 226019, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Digoxin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
To enhance the therapeutic efficacy and safety of triple-negative breast cancer (TNBC) treatment, we developed a hypoxia-responsive drug delivery system utilizing digoxin (DIG) to inhibit HIF-1α and sensitize TNBC to doxorubicin (DOX). DIG, a cardiac steroid with a well-characterized pharmacological mechanism, was encapsulated in micelles composed of methoxy-polyethylene glycol (mPEG) and poly(lactic acid) (PLA) copolymers, incorporating an azobenzene (AZO) trigger for hypoxia-sensitive drug release. The loading ratio of DOX to DIG was optimized based on DIG's minimum effective dose. In vitro and in vivo studies demonstrated that the micelles efficiently delivered their payload to hypoxic tumor regions, enabling rapid drug release. DIG-mediated HIF-1α inhibition enhanced TNBC sensitivity to DOX, leading to significant suppression of both primary tumor growth and pulmonary metastasis. This study presents a promising and clinically feasible strategy for TNBC and other hypoxia-driven malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Special Environmental Medicine, Medical School, Nantong University, Nantong 226019, China.
ORCID-Profile: Zhongping Chen, Li Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Weng, L., Zhao, M., Chen, Z., & Zhu, L. (2025). Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01325
Vancouver
Weng L, Zhao M, Chen Z, Zhu L. Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01325
BibTeX
@article{Weng2025,
author = {Weng, Lingyan and Zhao, Min and Chen, Zhongping and Zhu, Li},
title = {Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01325}
}
EUVIMED